Survival Benefit Confirmed in Real-Life Analysis of Second-Line Regorafenib in HCC
María Varela, MD, PhD, discusses the findings from a real-life analysis to confirm the benefit of regorafenib as treatment of patients with hepatocellular carcinoma who have progressed on prior sorafenib. Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
María Varela, MD, PhD, a pathologist in the Liver Unit at the Hospital Universitario Central de Asturias, discusses the findings from a real-life analysis to confirm the benefit of regorafenib (Stivarga) as treatment of patients with hepatocellular carcinoma (HCC) who have progressed on prior sorafenib (Nexavar). Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
If patients with HCC moved to regorafenib at the time of radiographic progression, they obtained better survival with regorafenib than if they stayed on sorafenib, Varela says. The survival for second-line regorafenib was estimated at 28 months versus 8 months with sorafenib, according to Varela.
There is some bias inthis real-life observational cohort
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
